In phase 2 cohorts, eligible patients had metastatic TNBC (cohort 2A) or hormone receptor-positive (HR+), HER2 negative, DNA damage repair defect-positive breast cancer (cohort 2B). Here, ERBB2 is linked to breast carcinoma.